This protein carries a human IgG1 Fc tag at the C-terminus. The protein has a calculated MW of 43.2 kDa. The protein migrates as 60-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
PDCD1
Spezies: Human
Wirt: HEK-293 Cells
Recombinant
The purity of the protein is greater than 90 % as determined by SDS-PAGE and Coomassie blue staining.
ELISA
PDCD1
Spezies: Human
Wirt: HEK-293 Cells
Recombinant
The purity of the protein is greater than 95 % as determined by SDS-PAGE and Coomassie blue staining.
ELISA
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Buffer
Tris with Glycine, Arginine and NaCl, pH 7.5
Handhabung
Please avoid repeated freeze-thaw cycles.
Lagerung
-20 °C
Informationen zur Lagerung
No activity loss was observed after storage at: In lyophilized state for 1 year (4 °C), After reconstitution under sterile conditions for 3 months (-70 °C).
Mukundan, Guan, Singleton, Yang, Li, Parekkadan: "Artificial T Cell Mimetics to Combat Melanoma Tumor Growth." in: American journal of advanced drug delivery, Vol. 6, Issue 1, pp. 21-32, (2018) (PubMed).
Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.